We assume that pharmaceutical tariffs will be enacted. While this could bring short-term margin pressure, we have not changed our valuations.

We are not changing our fair values to COVID-19 vaccine firms following the proposed waiver on intellectual property protection.

Covid will create a $52bn vaccine and treatment market and usher in immunity by 2023, writes Morningstar's Karen Andersen.

Resurgences in outbreaks make it clear that ending the pandemic requires more than testing, contact tracing, and social distancing, says...

We expect most US adults will be vaccinated in the first half of 2021, writes Morningstar healthcare strategist Karen Andersen.

Three new vaccines for coronavirus look poised for emergency use authorisation in the US this autumn. What does that mean for investors?

Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.

Christine Benz and Karen Andersen discuss Morningstar's latest views on stopping the spread of the virus as well as the economic implications.

A COVID-19 recession doesn't fit the mould of a 2008-style recession with longer-lasting economic impact.

The US is slowing the coronavirus spread as drug makers race toward a vaccine; while the longer-term economic effect will be modest, say Morningstar...